Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

Recs

1
Player Avatar DorminABC (99.91) Submitted: 7/14/2011 10:10:57 PM : Underperform Start Price: $8.10 GALT Score: +44.32

Who is John Galt?

Featured Broker Partners


Advertisement